Tilray Got Smoked, but Investors Should See Green Soon_老虎社区_美港股上老虎

Tilray Got Smoked, but Investors Should See Green Soon

InvestorPlace2021-12-27

As you may be aware, Canadian company Tilray (NASDAQ:TLRY) famously merged with Aphriaearlier this year, thereby creating the world’s biggest cannabis company by revenue. With that game-changing ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Nicole_L
·2021-12-28
I hope so!
回复
点赞
举报
littlekitten
·2021-12-27
.
回复
点赞
举报
RobinChanKH
·2021-12-27
Up
回复
2
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1137611466?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-27 13:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137611466","market":"us","top_or_hot":-1,"title":"Tilray Got Smoked, but Investors Should See Green Soon","media":"InvestorPlace","content":"<div>\n<p>As you may be aware, Canadian company Tilray (NASDAQ:TLRY) famously merged with Aphriaearlier this year, thereby creating the world’s biggest cannabis company by revenue. With that game-changing ...</p>\n\n<a href=\"https://investorplace.com/2021/12/tlry-stock-got-smoked-but-investors-should-see-green-soon/\">网页链接</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Got Smoked, but Investors Should See Green Soon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Got Smoked, but Investors Should See Green Soon\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 13:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/tlry-stock-got-smoked-but-investors-should-see-green-soon/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you may be aware, Canadian company Tilray (NASDAQ:TLRY) famously merged with Aphriaearlier this year, thereby creating the world’s biggest cannabis company by revenue. With that game-changing ...</p>\n\n<a href=\"https://investorplace.com/2021/12/tlry-stock-got-smoked-but-investors-should-see-green-soon/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLRY","symbol_name":"Tilray Inc.","start_time":0,"source_url":"https://investorplace.com/2021/12/tlry-stock-got-smoked-but-investors-should-see-green-soon/","article_id":"1137611466","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137611466","pubTimestamp":1640582999,"columns":[],"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"As you may be aware, Canadian company Tilray (NASDAQ:TLRY) famously merged with Aphriaearlier this y","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLRY":"Tilray Inc."},"translate_title":"Tilray被抽了，但投资者应该很快就会看到绿色","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLRY":0.9},"content_text":"As you may be aware, Canadian company Tilray (NASDAQ:TLRY) famously merged with Aphriaearlier this year, thereby creating the world’s biggest cannabis company by revenue. With that game-changing development, you’d think that TLRY stock would be a darling of the market.\nYet that’s far from the case. Sure, Tilray’s shares surged in February, but that enthusiasm is in the rear-view mirror now.\nToday the owners of TLRY stock must re-evaluate their positions and determine if it’s worthwhile to hold onto their shares. It can be painful to cut and run, but sometimes that’s just the best course of action.\nOn the other hand, the downturn of the shares may have created a rare buying opportunity. After all, Tilray just made a bold move into a high-potential cannabis niche market with an acquisition that’ll make you say, “I’ll drink to that.”\nA Closer Look at TLRY Stock\nWas it because of the Tilray-Aphria merger which was announced late last year? Or was it due to the Reddit-fueled short-squeeze?\nMaybe it was a combination of both. Either way, TLRY stock went on a wild ride in early 2021, culminating in a 52-week high of $67 on Feb. 10.\nBear in mind that the stock started off the year at $9. After a rally of that magnitude, you might assume that Tilray’s investors would end 2021 in the green.\nNot necessarily. As it turned out, TLRY stock declined nearly as quickly as it had ascended and even fell back below $9 this month. Yesterday the stock closed at $7.74.\nSo now it’s all about finding the stock’s bottom and rallying the troops, who could certainly use some positive news.\nDon’t Forget About Aphria\nWith so much going on in the world of cannabis stocks, it’s easy to ignore Aphria since the company isn’t a separately traded entity anymore.\nHowever, Aphria still has a significant presence in the market as the company is Tilray’smedical-cannabis subsidiary. Indeed, Aphria continues to innovate as a provider of medically beneficial cannabis-based products.\nRecently, for example, Tilray announced that Aphria had launched medical cannabis oral strips with THC- and CBD-rich options.\nThe Aphria medical strips contain a thin film with dissolving cannabinoids that are absorbed directly into the bloodstream. This methodology facilitates precise dosing and rapid ingestion.\nTilray Chairman and CEO Irwin D. Simon is a firm believer in medical cannabis, calling it a “high-growth, high-margin market.”\nAprhia’s medical-cannabis strips, which are already available throughout Canada, could prove to be a highly lucrative product.\nAn Iconic Addition\nWhile Tilray’s Aphria subsidiary probes the limits of medical cannabis, a newly added business could provide Tilray with access to a recreational section of the market.\nIn particular, Tilray recently revealed itsacquisition ofColorado-based distilled spirits platform Breckenridge Distillery.\nApparently, Breckenridge is known for its bourbon whiskey collection and craft spirits portfolio. Naturally, investors can expect Tilray to add some of its hemp-derived goodness to Breckenridge’s boozy offerings.\nCiting the company’s “award-winning spirits, passionate consumer engagement, and… strong sales and distribution network,” Simon, Tilray’s CEO, called Breckenridge Distillery an “iconic addition” to Tilray’s brands.\nWith this acquisition in mind, Tilray’s CEO has set an ambitious revenue objective.\nWith the expectation of launching “THC-based product adjacencies upon federal legalization in the U.S.,” Simon envisions an “ultimate goal of industry leadership with $4 billion in revenue by the end of fiscal year 2024.”\nThe Bottom Line\nIt’s fascinating to witness TLRY stock sink to new lows, even while Tilray is pushing the boundaries within the North American cannabis market.\nThere appears to be a mismatch between Tilray’s share price and the company’s true value.\nIn other words, contrarians should be jumping at the chance to buy the company’s shares now. Even if 2021 gave the investors a pop-and-drop, 2022 could be the year when Tilray’s “joint” ventures pay off.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":696862606,"gmtCreate":1640664606327,"gmtModify":1640664606435,"author":{"id":"3568809434693461","authorId":"3568809434693461","name":"Nicole_L","avatar":"https://static.tigerbbs.com/c6693db75e35e38dd7e6c673738552b7","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3568809434693461","authorIdStr":"3568809434693461"},"htmlText":"I hope so!&nbsp;","listText":"I hope so!&nbsp;","text":"I hope so!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696862606","repostId":1137611466,"repostType":2,"repost":{"id":"1137611466","kind":"news","pubTimestamp":1640582999,"share":"https://www.laohu8.com/m/news/1137611466?lang=&edition=full","pubTime":"2021-12-27 13:29","market":"us","language":"en","title":"Tilray Got Smoked, but Investors Should See Green Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=1137611466","media":"InvestorPlace","summary":"As you may be aware, Canadian company Tilray (NASDAQ:TLRY) famously merged with Aphriaearlier this y","content":"<p>As you may be aware, Canadian company&nbsp;<b>Tilray</b>&nbsp;(NASDAQ:<b><u>TLRY</u></b>)&nbsp;famously merged with Aphriaearlier this year, thereby creating the world’s biggest cannabis company by revenue. With that game-changing development, you’d think that TLRY stock would be a darling of the market.</p>\n<p>Yet that’s far from the case. Sure, Tilray’s shares surged in February, but that enthusiasm is in the rear-view mirror now.</p>\n<p>Today the owners of TLRY stock must re-evaluate their positions and determine if it’s worthwhile to hold onto their shares. It can be painful to cut and run, but sometimes that’s just the best course of action.</p>\n<p>On the other hand, the downturn of the shares may have created a rare buying opportunity. After all, Tilray just made a bold move into a high-potential cannabis niche market with an acquisition that’ll make you say, “I’ll drink to that.”</p>\n<p><b>A Closer Look at TLRY Stock</b></p>\n<p>Was it because of the Tilray-Aphria merger which&nbsp;was announced late last year? Or was it due to the&nbsp;<b>Reddit</b>-fueled short-squeeze?</p>\n<p>Maybe it was a combination of both. Either way, TLRY stock went on a wild ride in early 2021, culminating in a 52-week high of $67 on Feb. 10.</p>\n<p>Bear in mind that the stock started off the year at $9. After a rally of that magnitude, you might assume that Tilray’s investors would end 2021 in the green.</p>\n<p>Not necessarily. As it turned out, TLRY stock declined nearly as quickly as it had ascended and even fell back below $9 this month. Yesterday the stock closed at $7.74.</p>\n<p>So now it’s all about finding the stock’s bottom and rallying the troops, who could certainly use some positive news.</p>\n<p><b>Don’t Forget About Aphria</b></p>\n<p>With so much going on in the world of cannabis stocks, it’s easy to ignore Aphria since the company isn’t a separately traded entity anymore.</p>\n<p>However, Aphria still has a significant presence in the market as the company is Tilray’smedical-cannabis subsidiary. Indeed, Aphria continues to innovate as a provider of medically beneficial cannabis-based products.</p>\n<p>Recently, for example, Tilray announced that Aphria had launched medical cannabis oral strips with THC- and CBD-rich options.</p>\n<p>The Aphria medical strips contain a thin film with dissolving cannabinoids that are absorbed directly into the bloodstream. This methodology facilitates precise dosing and rapid ingestion.</p>\n<p>Tilray Chairman and CEO Irwin D. Simon is a firm believer in medical cannabis, calling it a “high-growth, high-margin market.”</p>\n<p>Aprhia’s medical-cannabis strips, which are already available throughout Canada, could prove to be a highly lucrative product.</p>\n<p><b>An Iconic Addition</b></p>\n<p>While Tilray’s Aphria subsidiary probes the limits of medical cannabis, a newly added business could provide Tilray with access to a recreational section of the market.</p>\n<p>In particular, Tilray recently revealed itsacquisition ofColorado-based distilled spirits platform Breckenridge Distillery.</p>\n<p>Apparently, Breckenridge&nbsp;is known for its bourbon whiskey collection and craft spirits portfolio. Naturally, investors can expect Tilray to add some of its hemp-derived goodness to Breckenridge’s boozy offerings.</p>\n<p>Citing the company’s “award-winning spirits, passionate consumer engagement, and… strong sales and distribution network,” Simon, Tilray’s CEO, called Breckenridge Distillery an “iconic addition” to Tilray’s brands.</p>\n<p>With this acquisition in mind, Tilray’s CEO has set an ambitious revenue objective.</p>\n<p>With the expectation of launching “THC-based product adjacencies upon federal legalization in the U.S.,” Simon envisions an “ultimate goal of industry leadership with $4 billion in revenue by the end of fiscal year 2024.”</p>\n<p><b>The Bottom Line</b></p>\n<p>It’s fascinating to witness TLRY stock sink to new lows, even while Tilray is pushing the boundaries within the North American cannabis market.</p>\n<p>There appears to be a mismatch between Tilray’s share price and the company’s true value.</p>\n<p>In other words, contrarians should be jumping at the chance to buy the company’s shares now. Even if 2021 gave the investors a pop-and-drop, 2022 could be the year when Tilray’s “joint” ventures pay off.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Got Smoked, but Investors Should See Green Soon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Got Smoked, but Investors Should See Green Soon\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 13:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/tlry-stock-got-smoked-but-investors-should-see-green-soon/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you may be aware, Canadian company Tilray (NASDAQ:TLRY) famously merged with Aphriaearlier this year, thereby creating the world’s biggest cannabis company by revenue. With that game-changing ...</p>\n\n<a href=\"https://investorplace.com/2021/12/tlry-stock-got-smoked-but-investors-should-see-green-soon/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://investorplace.com/2021/12/tlry-stock-got-smoked-but-investors-should-see-green-soon/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137611466","content_text":"As you may be aware, Canadian company Tilray (NASDAQ:TLRY) famously merged with Aphriaearlier this year, thereby creating the world’s biggest cannabis company by revenue. With that game-changing development, you’d think that TLRY stock would be a darling of the market.\nYet that’s far from the case. Sure, Tilray’s shares surged in February, but that enthusiasm is in the rear-view mirror now.\nToday the owners of TLRY stock must re-evaluate their positions and determine if it’s worthwhile to hold onto their shares. It can be painful to cut and run, but sometimes that’s just the best course of action.\nOn the other hand, the downturn of the shares may have created a rare buying opportunity. After all, Tilray just made a bold move into a high-potential cannabis niche market with an acquisition that’ll make you say, “I’ll drink to that.”\nA Closer Look at TLRY Stock\nWas it because of the Tilray-Aphria merger which was announced late last year? Or was it due to the Reddit-fueled short-squeeze?\nMaybe it was a combination of both. Either way, TLRY stock went on a wild ride in early 2021, culminating in a 52-week high of $67 on Feb. 10.\nBear in mind that the stock started off the year at $9. After a rally of that magnitude, you might assume that Tilray’s investors would end 2021 in the green.\nNot necessarily. As it turned out, TLRY stock declined nearly as quickly as it had ascended and even fell back below $9 this month. Yesterday the stock closed at $7.74.\nSo now it’s all about finding the stock’s bottom and rallying the troops, who could certainly use some positive news.\nDon’t Forget About Aphria\nWith so much going on in the world of cannabis stocks, it’s easy to ignore Aphria since the company isn’t a separately traded entity anymore.\nHowever, Aphria still has a significant presence in the market as the company is Tilray’smedical-cannabis subsidiary. Indeed, Aphria continues to innovate as a provider of medically beneficial cannabis-based products.\nRecently, for example, Tilray announced that Aphria had launched medical cannabis oral strips with THC- and CBD-rich options.\nThe Aphria medical strips contain a thin film with dissolving cannabinoids that are absorbed directly into the bloodstream. This methodology facilitates precise dosing and rapid ingestion.\nTilray Chairman and CEO Irwin D. Simon is a firm believer in medical cannabis, calling it a “high-growth, high-margin market.”\nAprhia’s medical-cannabis strips, which are already available throughout Canada, could prove to be a highly lucrative product.\nAn Iconic Addition\nWhile Tilray’s Aphria subsidiary probes the limits of medical cannabis, a newly added business could provide Tilray with access to a recreational section of the market.\nIn particular, Tilray recently revealed itsacquisition ofColorado-based distilled spirits platform Breckenridge Distillery.\nApparently, Breckenridge is known for its bourbon whiskey collection and craft spirits portfolio. Naturally, investors can expect Tilray to add some of its hemp-derived goodness to Breckenridge’s boozy offerings.\nCiting the company’s “award-winning spirits, passionate consumer engagement, and… strong sales and distribution network,” Simon, Tilray’s CEO, called Breckenridge Distillery an “iconic addition” to Tilray’s brands.\nWith this acquisition in mind, Tilray’s CEO has set an ambitious revenue objective.\nWith the expectation of launching “THC-based product adjacencies upon federal legalization in the U.S.,” Simon envisions an “ultimate goal of industry leadership with $4 billion in revenue by the end of fiscal year 2024.”\nThe Bottom Line\nIt’s fascinating to witness TLRY stock sink to new lows, even while Tilray is pushing the boundaries within the North American cannabis market.\nThere appears to be a mismatch between Tilray’s share price and the company’s true value.\nIn other words, contrarians should be jumping at the chance to buy the company’s shares now. Even if 2021 gave the investors a pop-and-drop, 2022 could be the year when Tilray’s “joint” ventures pay off.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":696975050,"gmtCreate":1640612243558,"gmtModify":1640612244005,"author":{"id":"3584860762907200","authorId":"3584860762907200","name":"littlekitten","avatar":"https://static.tigerbbs.com/ccd59ff6c96999c839e3b5709cfb00ef","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3584860762907200","authorIdStr":"3584860762907200"},"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696975050","repostId":1137611466,"repostType":4,"repost":{"id":"1137611466","kind":"news","pubTimestamp":1640582999,"share":"https://www.laohu8.com/m/news/1137611466?lang=&edition=full","pubTime":"2021-12-27 13:29","market":"us","language":"en","title":"Tilray Got Smoked, but Investors Should See Green Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=1137611466","media":"InvestorPlace","summary":"As you may be aware, Canadian company Tilray (NASDAQ:TLRY) famously merged with Aphriaearlier this y","content":"<p>As you may be aware, Canadian company&nbsp;<b>Tilray</b>&nbsp;(NASDAQ:<b><u>TLRY</u></b>)&nbsp;famously merged with Aphriaearlier this year, thereby creating the world’s biggest cannabis company by revenue. With that game-changing development, you’d think that TLRY stock would be a darling of the market.</p>\n<p>Yet that’s far from the case. Sure, Tilray’s shares surged in February, but that enthusiasm is in the rear-view mirror now.</p>\n<p>Today the owners of TLRY stock must re-evaluate their positions and determine if it’s worthwhile to hold onto their shares. It can be painful to cut and run, but sometimes that’s just the best course of action.</p>\n<p>On the other hand, the downturn of the shares may have created a rare buying opportunity. After all, Tilray just made a bold move into a high-potential cannabis niche market with an acquisition that’ll make you say, “I’ll drink to that.”</p>\n<p><b>A Closer Look at TLRY Stock</b></p>\n<p>Was it because of the Tilray-Aphria merger which&nbsp;was announced late last year? Or was it due to the&nbsp;<b>Reddit</b>-fueled short-squeeze?</p>\n<p>Maybe it was a combination of both. Either way, TLRY stock went on a wild ride in early 2021, culminating in a 52-week high of $67 on Feb. 10.</p>\n<p>Bear in mind that the stock started off the year at $9. After a rally of that magnitude, you might assume that Tilray’s investors would end 2021 in the green.</p>\n<p>Not necessarily. As it turned out, TLRY stock declined nearly as quickly as it had ascended and even fell back below $9 this month. Yesterday the stock closed at $7.74.</p>\n<p>So now it’s all about finding the stock’s bottom and rallying the troops, who could certainly use some positive news.</p>\n<p><b>Don’t Forget About Aphria</b></p>\n<p>With so much going on in the world of cannabis stocks, it’s easy to ignore Aphria since the company isn’t a separately traded entity anymore.</p>\n<p>However, Aphria still has a significant presence in the market as the company is Tilray’smedical-cannabis subsidiary. Indeed, Aphria continues to innovate as a provider of medically beneficial cannabis-based products.</p>\n<p>Recently, for example, Tilray announced that Aphria had launched medical cannabis oral strips with THC- and CBD-rich options.</p>\n<p>The Aphria medical strips contain a thin film with dissolving cannabinoids that are absorbed directly into the bloodstream. This methodology facilitates precise dosing and rapid ingestion.</p>\n<p>Tilray Chairman and CEO Irwin D. Simon is a firm believer in medical cannabis, calling it a “high-growth, high-margin market.”</p>\n<p>Aprhia’s medical-cannabis strips, which are already available throughout Canada, could prove to be a highly lucrative product.</p>\n<p><b>An Iconic Addition</b></p>\n<p>While Tilray’s Aphria subsidiary probes the limits of medical cannabis, a newly added business could provide Tilray with access to a recreational section of the market.</p>\n<p>In particular, Tilray recently revealed itsacquisition ofColorado-based distilled spirits platform Breckenridge Distillery.</p>\n<p>Apparently, Breckenridge&nbsp;is known for its bourbon whiskey collection and craft spirits portfolio. Naturally, investors can expect Tilray to add some of its hemp-derived goodness to Breckenridge’s boozy offerings.</p>\n<p>Citing the company’s “award-winning spirits, passionate consumer engagement, and… strong sales and distribution network,” Simon, Tilray’s CEO, called Breckenridge Distillery an “iconic addition” to Tilray’s brands.</p>\n<p>With this acquisition in mind, Tilray’s CEO has set an ambitious revenue objective.</p>\n<p>With the expectation of launching “THC-based product adjacencies upon federal legalization in the U.S.,” Simon envisions an “ultimate goal of industry leadership with $4 billion in revenue by the end of fiscal year 2024.”</p>\n<p><b>The Bottom Line</b></p>\n<p>It’s fascinating to witness TLRY stock sink to new lows, even while Tilray is pushing the boundaries within the North American cannabis market.</p>\n<p>There appears to be a mismatch between Tilray’s share price and the company’s true value.</p>\n<p>In other words, contrarians should be jumping at the chance to buy the company’s shares now. Even if 2021 gave the investors a pop-and-drop, 2022 could be the year when Tilray’s “joint” ventures pay off.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Got Smoked, but Investors Should See Green Soon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Got Smoked, but Investors Should See Green Soon\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 13:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/tlry-stock-got-smoked-but-investors-should-see-green-soon/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you may be aware, Canadian company Tilray (NASDAQ:TLRY) famously merged with Aphriaearlier this year, thereby creating the world’s biggest cannabis company by revenue. With that game-changing ...</p>\n\n<a href=\"https://investorplace.com/2021/12/tlry-stock-got-smoked-but-investors-should-see-green-soon/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://investorplace.com/2021/12/tlry-stock-got-smoked-but-investors-should-see-green-soon/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137611466","content_text":"As you may be aware, Canadian company Tilray (NASDAQ:TLRY) famously merged with Aphriaearlier this year, thereby creating the world’s biggest cannabis company by revenue. With that game-changing development, you’d think that TLRY stock would be a darling of the market.\nYet that’s far from the case. Sure, Tilray’s shares surged in February, but that enthusiasm is in the rear-view mirror now.\nToday the owners of TLRY stock must re-evaluate their positions and determine if it’s worthwhile to hold onto their shares. It can be painful to cut and run, but sometimes that’s just the best course of action.\nOn the other hand, the downturn of the shares may have created a rare buying opportunity. After all, Tilray just made a bold move into a high-potential cannabis niche market with an acquisition that’ll make you say, “I’ll drink to that.”\nA Closer Look at TLRY Stock\nWas it because of the Tilray-Aphria merger which was announced late last year? Or was it due to the Reddit-fueled short-squeeze?\nMaybe it was a combination of both. Either way, TLRY stock went on a wild ride in early 2021, culminating in a 52-week high of $67 on Feb. 10.\nBear in mind that the stock started off the year at $9. After a rally of that magnitude, you might assume that Tilray’s investors would end 2021 in the green.\nNot necessarily. As it turned out, TLRY stock declined nearly as quickly as it had ascended and even fell back below $9 this month. Yesterday the stock closed at $7.74.\nSo now it’s all about finding the stock’s bottom and rallying the troops, who could certainly use some positive news.\nDon’t Forget About Aphria\nWith so much going on in the world of cannabis stocks, it’s easy to ignore Aphria since the company isn’t a separately traded entity anymore.\nHowever, Aphria still has a significant presence in the market as the company is Tilray’smedical-cannabis subsidiary. Indeed, Aphria continues to innovate as a provider of medically beneficial cannabis-based products.\nRecently, for example, Tilray announced that Aphria had launched medical cannabis oral strips with THC- and CBD-rich options.\nThe Aphria medical strips contain a thin film with dissolving cannabinoids that are absorbed directly into the bloodstream. This methodology facilitates precise dosing and rapid ingestion.\nTilray Chairman and CEO Irwin D. Simon is a firm believer in medical cannabis, calling it a “high-growth, high-margin market.”\nAprhia’s medical-cannabis strips, which are already available throughout Canada, could prove to be a highly lucrative product.\nAn Iconic Addition\nWhile Tilray’s Aphria subsidiary probes the limits of medical cannabis, a newly added business could provide Tilray with access to a recreational section of the market.\nIn particular, Tilray recently revealed itsacquisition ofColorado-based distilled spirits platform Breckenridge Distillery.\nApparently, Breckenridge is known for its bourbon whiskey collection and craft spirits portfolio. Naturally, investors can expect Tilray to add some of its hemp-derived goodness to Breckenridge’s boozy offerings.\nCiting the company’s “award-winning spirits, passionate consumer engagement, and… strong sales and distribution network,” Simon, Tilray’s CEO, called Breckenridge Distillery an “iconic addition” to Tilray’s brands.\nWith this acquisition in mind, Tilray’s CEO has set an ambitious revenue objective.\nWith the expectation of launching “THC-based product adjacencies upon federal legalization in the U.S.,” Simon envisions an “ultimate goal of industry leadership with $4 billion in revenue by the end of fiscal year 2024.”\nThe Bottom Line\nIt’s fascinating to witness TLRY stock sink to new lows, even while Tilray is pushing the boundaries within the North American cannabis market.\nThere appears to be a mismatch between Tilray’s share price and the company’s true value.\nIn other words, contrarians should be jumping at the chance to buy the company’s shares now. Even if 2021 gave the investors a pop-and-drop, 2022 could be the year when Tilray’s “joint” ventures pay off.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":696070520,"gmtCreate":1640585499315,"gmtModify":1640585499732,"author":{"id":"3585125163446793","authorId":"3585125163446793","name":"RobinChanKH","avatar":"https://static.tigerbbs.com/bf0ba843eca17a8812677bc4f2a46162","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3585125163446793","authorIdStr":"3585125163446793"},"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696070520","repostId":1137611466,"repostType":4,"repost":{"id":"1137611466","kind":"news","pubTimestamp":1640582999,"share":"https://www.laohu8.com/m/news/1137611466?lang=&edition=full","pubTime":"2021-12-27 13:29","market":"us","language":"en","title":"Tilray Got Smoked, but Investors Should See Green Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=1137611466","media":"InvestorPlace","summary":"As you may be aware, Canadian company Tilray (NASDAQ:TLRY) famously merged with Aphriaearlier this y","content":"<p>As you may be aware, Canadian company&nbsp;<b>Tilray</b>&nbsp;(NASDAQ:<b><u>TLRY</u></b>)&nbsp;famously merged with Aphriaearlier this year, thereby creating the world’s biggest cannabis company by revenue. With that game-changing development, you’d think that TLRY stock would be a darling of the market.</p>\n<p>Yet that’s far from the case. Sure, Tilray’s shares surged in February, but that enthusiasm is in the rear-view mirror now.</p>\n<p>Today the owners of TLRY stock must re-evaluate their positions and determine if it’s worthwhile to hold onto their shares. It can be painful to cut and run, but sometimes that’s just the best course of action.</p>\n<p>On the other hand, the downturn of the shares may have created a rare buying opportunity. After all, Tilray just made a bold move into a high-potential cannabis niche market with an acquisition that’ll make you say, “I’ll drink to that.”</p>\n<p><b>A Closer Look at TLRY Stock</b></p>\n<p>Was it because of the Tilray-Aphria merger which&nbsp;was announced late last year? Or was it due to the&nbsp;<b>Reddit</b>-fueled short-squeeze?</p>\n<p>Maybe it was a combination of both. Either way, TLRY stock went on a wild ride in early 2021, culminating in a 52-week high of $67 on Feb. 10.</p>\n<p>Bear in mind that the stock started off the year at $9. After a rally of that magnitude, you might assume that Tilray’s investors would end 2021 in the green.</p>\n<p>Not necessarily. As it turned out, TLRY stock declined nearly as quickly as it had ascended and even fell back below $9 this month. Yesterday the stock closed at $7.74.</p>\n<p>So now it’s all about finding the stock’s bottom and rallying the troops, who could certainly use some positive news.</p>\n<p><b>Don’t Forget About Aphria</b></p>\n<p>With so much going on in the world of cannabis stocks, it’s easy to ignore Aphria since the company isn’t a separately traded entity anymore.</p>\n<p>However, Aphria still has a significant presence in the market as the company is Tilray’smedical-cannabis subsidiary. Indeed, Aphria continues to innovate as a provider of medically beneficial cannabis-based products.</p>\n<p>Recently, for example, Tilray announced that Aphria had launched medical cannabis oral strips with THC- and CBD-rich options.</p>\n<p>The Aphria medical strips contain a thin film with dissolving cannabinoids that are absorbed directly into the bloodstream. This methodology facilitates precise dosing and rapid ingestion.</p>\n<p>Tilray Chairman and CEO Irwin D. Simon is a firm believer in medical cannabis, calling it a “high-growth, high-margin market.”</p>\n<p>Aprhia’s medical-cannabis strips, which are already available throughout Canada, could prove to be a highly lucrative product.</p>\n<p><b>An Iconic Addition</b></p>\n<p>While Tilray’s Aphria subsidiary probes the limits of medical cannabis, a newly added business could provide Tilray with access to a recreational section of the market.</p>\n<p>In particular, Tilray recently revealed itsacquisition ofColorado-based distilled spirits platform Breckenridge Distillery.</p>\n<p>Apparently, Breckenridge&nbsp;is known for its bourbon whiskey collection and craft spirits portfolio. Naturally, investors can expect Tilray to add some of its hemp-derived goodness to Breckenridge’s boozy offerings.</p>\n<p>Citing the company’s “award-winning spirits, passionate consumer engagement, and… strong sales and distribution network,” Simon, Tilray’s CEO, called Breckenridge Distillery an “iconic addition” to Tilray’s brands.</p>\n<p>With this acquisition in mind, Tilray’s CEO has set an ambitious revenue objective.</p>\n<p>With the expectation of launching “THC-based product adjacencies upon federal legalization in the U.S.,” Simon envisions an “ultimate goal of industry leadership with $4 billion in revenue by the end of fiscal year 2024.”</p>\n<p><b>The Bottom Line</b></p>\n<p>It’s fascinating to witness TLRY stock sink to new lows, even while Tilray is pushing the boundaries within the North American cannabis market.</p>\n<p>There appears to be a mismatch between Tilray’s share price and the company’s true value.</p>\n<p>In other words, contrarians should be jumping at the chance to buy the company’s shares now. Even if 2021 gave the investors a pop-and-drop, 2022 could be the year when Tilray’s “joint” ventures pay off.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Got Smoked, but Investors Should See Green Soon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Got Smoked, but Investors Should See Green Soon\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 13:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/tlry-stock-got-smoked-but-investors-should-see-green-soon/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you may be aware, Canadian company Tilray (NASDAQ:TLRY) famously merged with Aphriaearlier this year, thereby creating the world’s biggest cannabis company by revenue. With that game-changing ...</p>\n\n<a href=\"https://investorplace.com/2021/12/tlry-stock-got-smoked-but-investors-should-see-green-soon/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://investorplace.com/2021/12/tlry-stock-got-smoked-but-investors-should-see-green-soon/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137611466","content_text":"As you may be aware, Canadian company Tilray (NASDAQ:TLRY) famously merged with Aphriaearlier this year, thereby creating the world’s biggest cannabis company by revenue. With that game-changing development, you’d think that TLRY stock would be a darling of the market.\nYet that’s far from the case. Sure, Tilray’s shares surged in February, but that enthusiasm is in the rear-view mirror now.\nToday the owners of TLRY stock must re-evaluate their positions and determine if it’s worthwhile to hold onto their shares. It can be painful to cut and run, but sometimes that’s just the best course of action.\nOn the other hand, the downturn of the shares may have created a rare buying opportunity. After all, Tilray just made a bold move into a high-potential cannabis niche market with an acquisition that’ll make you say, “I’ll drink to that.”\nA Closer Look at TLRY Stock\nWas it because of the Tilray-Aphria merger which was announced late last year? Or was it due to the Reddit-fueled short-squeeze?\nMaybe it was a combination of both. Either way, TLRY stock went on a wild ride in early 2021, culminating in a 52-week high of $67 on Feb. 10.\nBear in mind that the stock started off the year at $9. After a rally of that magnitude, you might assume that Tilray’s investors would end 2021 in the green.\nNot necessarily. As it turned out, TLRY stock declined nearly as quickly as it had ascended and even fell back below $9 this month. Yesterday the stock closed at $7.74.\nSo now it’s all about finding the stock’s bottom and rallying the troops, who could certainly use some positive news.\nDon’t Forget About Aphria\nWith so much going on in the world of cannabis stocks, it’s easy to ignore Aphria since the company isn’t a separately traded entity anymore.\nHowever, Aphria still has a significant presence in the market as the company is Tilray’smedical-cannabis subsidiary. Indeed, Aphria continues to innovate as a provider of medically beneficial cannabis-based products.\nRecently, for example, Tilray announced that Aphria had launched medical cannabis oral strips with THC- and CBD-rich options.\nThe Aphria medical strips contain a thin film with dissolving cannabinoids that are absorbed directly into the bloodstream. This methodology facilitates precise dosing and rapid ingestion.\nTilray Chairman and CEO Irwin D. Simon is a firm believer in medical cannabis, calling it a “high-growth, high-margin market.”\nAprhia’s medical-cannabis strips, which are already available throughout Canada, could prove to be a highly lucrative product.\nAn Iconic Addition\nWhile Tilray’s Aphria subsidiary probes the limits of medical cannabis, a newly added business could provide Tilray with access to a recreational section of the market.\nIn particular, Tilray recently revealed itsacquisition ofColorado-based distilled spirits platform Breckenridge Distillery.\nApparently, Breckenridge is known for its bourbon whiskey collection and craft spirits portfolio. Naturally, investors can expect Tilray to add some of its hemp-derived goodness to Breckenridge’s boozy offerings.\nCiting the company’s “award-winning spirits, passionate consumer engagement, and… strong sales and distribution network,” Simon, Tilray’s CEO, called Breckenridge Distillery an “iconic addition” to Tilray’s brands.\nWith this acquisition in mind, Tilray’s CEO has set an ambitious revenue objective.\nWith the expectation of launching “THC-based product adjacencies upon federal legalization in the U.S.,” Simon envisions an “ultimate goal of industry leadership with $4 billion in revenue by the end of fiscal year 2024.”\nThe Bottom Line\nIt’s fascinating to witness TLRY stock sink to new lows, even while Tilray is pushing the boundaries within the North American cannabis market.\nThere appears to be a mismatch between Tilray’s share price and the company’s true value.\nIn other words, contrarians should be jumping at the chance to buy the company’s shares now. Even if 2021 gave the investors a pop-and-drop, 2022 could be the year when Tilray’s “joint” ventures pay off.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":26,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}